Clinical trials: Covid19 Vaccine
COVID
Evaluation of Immunogenicity of COVID-19 Vaccine in Chinese Population
The purpose of this study is to evaluate the immunogenicity and immune protection of COVID-19, especially the recently prevalent strains, against the background of current immunization in Chinese population
- Trial name
- NCT06763887
- Testing
- No Interventions
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Xijing Hospital
Vaccine Response Impaired, Vaccine Adverse Reaction
Vaccine Observation to Include All Communities for Equitable Science
VOICES is a longitudinal, prospective, observational study that will enroll up to 10,000 subjects of diverse racial backgrounds being administered an emergency use authorized COVID-19 vaccine, for collection and analysis of stool…
- Trial name
- VOICES (NCT04770649)
- Testing
- COVID-19 vaccine
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Persephone Biosciences
COVID-19
Safety, Reactogenicity, and Immunogenicity Trial of STX-S SARS-CoV-2 Vaccine in Adults
This phase 1 clinical trial will evaluate the safety, reactogenicity, and immunogenicity of STX-S in adults who have previously received a primary series and at least one booster with an authorized or licensed SARS-CoV-2…
- Trial name
- NCT07095231
- Testing
- STX-S
- Where
- 3 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
COVID-19 Fourth Dose Study in Australia
This clinical trial will be a blinded, randomised study to determine the safety, reactogenicity, and immunogenicity of a second booster dose of SARS-CoV-2 vaccines in adults enrolled over two consecutive stages.
- Trial name
- NCT05543356
- Testing
- Tozinameran, Elasomeran, Bivalent Pfizer-BioNTech
- Where
- Australia
- Volunteers
- healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute
COVID-19, SARS-CoV-2 Acute Respiratory Disease
Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration.
This Phase IIb clinical study aims to compare the immunogenicity and safety of a booster dose of recombinant protein RBD fusion dimer vaccine as a heterologous booster (to subjects who have received the second dose of the…
- Trial name
- NCT05142553
- Testing
- COVID-19 Vaccine HIPRA, Cominarty (Pfizer-BioNtech)
- Where
- 10 sites in Spain
- Volunteers
- 887 people, healthy volunteers welcome
- Sponsor
- Hipra Scientific, S.L.U
COVID-19
Long COVID-19 and MAB Study
This study will be observational only. It will provide real-world evidence generated from a representative and large-scale COVID patient base.
- Trial name
- NCT05508295
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- MultiCare Health System Research Institute
SARS-CoV-2 Infection, COVID-19
Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants
This trial consisted of three parts, Part A, Part B, and Part C, and evaluated the safety and immunogenicity of a third (booster) injection of the multivalent vaccine BNT162b2 (B.1.1.7 + B.1.617.2), and the safety and…
- Conditions
- SARS-CoV-2 Infection, COVID-19, SARS-CoV-2 Acute Respiratory Disease, SARS (Disease)
- Trial name
- NCT05004181
- Testing
- BNT162b2, Multivalent BNT162b2 (B.1.1.7 + B.1.617.2), Monovalent BNT162b2 (B.1.1.7)
- Where
- 35 sites in United States, Germany and 2 more
- Volunteers
- 1,380 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
SARS-CoV-2
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants
The study evaluated the safety, tolerability, reactogenicity, and effectiveness of mRNA-1273.214 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in infants aged 12 weeks to < 6 months.
- Trial name
- BabyCOVE (NCT05584202)
- Testing
- mRNA-1273.214
- Where
- 39 sites in United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Covid19, Measles Vaccine
Do Childhood Measles and DTaP Vaccination Decrease the Mortality Rate Caused by COVID-19 in OECD Countries?
Mortality rates caused by SARS CoV-2 differ between countries and this difference might be explained by several reasons. Childhood vaccination rate is thought to be one of them.
- Conditions
- Covid19, Measles Vaccine, Mortality
- Trial name
- NCT04468802
- Testing
- Case fatality rate
- Where
- Turkey (Türkiye)
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Kanuni Sultan Suleyman Training and Research Hospital
Vaccine-Preventable Diseases, Vaccine Refusal
Volatility and Heterogeneity of Vaccine Sentiments Means Continuous Monitoring is Needed When Measuring Message Effectiveness
The success of vaccination programs often depends on the effectiveness of the vaccine messages, particularly during emergencies such as the COVID-19 pandemic.
- Trial name
- NCT05499299
- Testing
- Google ads
- Where
- Hong Kong
- Volunteers
- 127,000 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
COVID-19
Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Children and Adolescents
This study is a randomized, double-blinded, placebo-controlled, phase Ⅱb clinical trial of an inactivated SARS-CoV-2 vaccine (CoronaVac) manufactured by Sinovac Life Sciences Co.
- Trial name
- NCT04884685
- Testing
- SARS-CoV-2 Inactivated Vaccine
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Breastfeeding, COVID-19 Infection
Researchers At UC San Diego Are Learning About the Benefits of Human Milk and How It Influences Infant and Child Health
The purpose of the UCSD Human Milk Biorepository is to establish and maintain a repository of breast milk samples that can be used to learn more about how breast milk influences infant and child health.
- Conditions
- Breastfeeding, COVID-19 Infection, COVID-19 Vaccine, Remdesivir
- Trial name
- NCT05553743
- Testing
- COVID-19 Exposure, Antibiotic
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Covid19
Covid-19 Vaccination in Adolescents and Children
Objectives To assess the reactogenicity, measure the adaptive immune responses and track the long-term immune memory in healthy children and adults as well as pediatric patients receiving the COVID-19 vaccines-BNT162b2…
- Trial name
- COVAC (NCT04800133)
- Testing
- Tozinameran, CoronaVac, CoronaVac, intradermal
- Where
- China
- Volunteers
- 1,018 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
COVID-19, SARS-CoV-2
Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants
Prevention of COVID-19 caused by SARS-CoV-2.
- Trial name
- NCT05260437
- Testing
- CV2CoV (2 µg), CV2CoV (4 µg), CV2CoV (8 µg)
- Where
- 24 sites in United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19 Vaccine
ARVAC - A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine
The objective of this clinical trial is to test a new vaccine against SARS-CoV-2 (ARVAC-CG) in healthy adult volunteers, previously vaccinated against the SARS-CoV-2 virus.
- Trial name
- NCT05656508
- Testing
- ARVAC-CG vaccine (recombinant protein vaccine against SARS-CoV-2)
- Where
- Argentina
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Laboratorio Pablo Cassara S.R.L.
Long COVID, Fatigue
Long COVID-19 Fatigue and Obstructive Sleep Apnea
Identify the relationship of obstructive sleep apnea (OSA) prevalence with post-COVID-19 fatigue that remains at least six months after acute disease
- Conditions
- Long COVID, Fatigue, Obstructive Sleep Apnea of Adult
- Trial name
- PostCoV2OSA (NCT05290350)
- Testing
- OSA
- Where
- 12 sites in Portugal
- Volunteers
- 300 people
- Sponsor
- Centro Hospitalar Universitario do Algarve
COVID-19
Immunogenicity and Safety of Booster Immunization of COVID-19 Vaccine (Vero Cell), Inactivated (Omicron Variant) in Healthy People Aged 18 Years and Above
This is a randomized, double-blind, active-controlled Phase Ⅲ clinical trial, as well as an immuno-bridging clinical trial by parallel testing previous serum after primary immunization of COVID-19 vaccine (Vero cell), inactivated…
- Trial name
- NCT05381350
- Testing
- COVID-19 Vaccine (Vero cell), Inactivated (Omicron variant), COVID-19 Vaccine (Vero cell), Inactivated (CZ strain)
- Where
- China
- Volunteers
- 1,750 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
COVID-19
Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19)
This study is a randomized, double-blinded, and placebo controlled phase Ⅰ/Ⅱ clinical trial of the SARS-CoV-2 inactivated vaccine manufactured by Sinovac Research \& Development Co., Ltd.
- Trial name
- NCT04352608
- Testing
- Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule, Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule, Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
- Where
- China
- Volunteers
- 744 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
Post-Acute COVID-19 Vaccination Syndrome, Postviral Fatigue
Clinical Laboratory Evaluation, Assessment of Symptoms and Recovery in Patients With Post-COVID-19-Vaccination Syndrome
Some people report persistent health problems after receiving the COVID-19 vaccine. These symptoms persist well beyond typical short-term vaccine side effects and are not attributable to any other known medical conditions.
- Trial name
- CLEAR (NCT07400848)
- Testing
- Blood sampling and analysis, The continuous Reactive Hyperemia Index (InRHI) measured by EndoPAT
- Where
- Switzerland
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Bern
COVID-19 Vaccine
Phase IIB Study of Recombinant Novel Coronavirus Vaccine
This is an open-label and non-randomized study to demonstrate the immunogenicity and safety profile in adults that received the Ad5-nCoV vaccine at least 21 days but no later than 90 days after the first dose of Sputnik V.
- Trial name
- FH-63 (NCT05293223)
- Testing
- Ad5-nCov
- Where
- 3 sites in Argentina
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Fundación Huésped
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.